Filing Flows › Biogen (BIIB) › Stock forecast & fair value
Biogen (BIIB) stock forecast and fair value
Biogen (BIIB) trades at $248.35. 32 analysts' median price target is $270.00 (+9%), from $175.00 to $350.00. Across 18 valuation methods the middle fair value is $133.29 (-46%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| P/E vs peers | $42.67 | $58.66 | $82.93 | -76% |
| P/E vs peers, weighted | $49.07 | $60.91 | $95.84 | -75% |
| P/E vs peers, matched | $36.84 | $71.20 | $104.23 | -71% |
| EV/Sales vs peers | $429.83 | $482.65 | $1,055.27 | +94% |
| EV/Sales vs peers, weighted | $330.05 | $402.65 | $487.42 | +62% |
| EV/Sales vs peers, matched | $56.37 | $107.21 | $223.52 | -57% |
| Residual income | $94.89 | $98.52 | $102.38 | -60% |
| Sum of the parts (segments × peer EV/Sales) | $413.65 | $487.54 | $1,055.13 | +96% |
| Sum of the parts, weighted (segments × weighted peer EV/Sales) | $344.68 | $438.80 | $549.86 | +77% |
| Analysts' price targets | $175.00 | $266.38 | $350.00 | +7% |
Biogen's latest quarter
Biogen, Q3 2026: revenue $2.8B (+11% year over year), operating margin -0.3%, net loss $20.6M, operating cash flow $641M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for BIIB stock?
The median of 32 analysts' 12-month targets is $270.00, +9% from $248.35; the range is $175.00 to $350.00. The average rating is buy.
What is Biogen's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $0.00 and $487.54, with a middle value of $133.29 against a price of $248.35. Each method's assumptions are on the page.
Does Biogen usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is BIIB stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.